Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain H Rook

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|July 31, 2012
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsinYoun H Kim, Marie-France Demierre, Ellen J Kim, et al.
The Journal of Investigative Dermatology|August 24, 2007
IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndromeJessica S Yoon, Sarah M Newton, Maria Wysocka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2013
TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphomaEmmanuella Guenova, Rei Watanabe, Jessica E Teague, et al.
Journal of the American Academy of Dermatology|February 19, 2013
Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapyRachel S Klein, James D Dunlop, Sara S Samimi, et al.
Blood|January 13, 2006
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracyMichael Nebozhyn, Andrey Loboda, Laszlo Kari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaSean J Whittaker, Marie-France Demierre, Ellen J Kim, et al.
JAMA Dermatology|December 30, 2020
Brentuximab Vedotin for Relapsed or Refractory Sézary SyndromeDaniel J Lewis, Paul L Haun, Sara S Samimi, et al.
Blood Advances|April 14, 2023
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphomaKeisuke Watanabe, Angela M Gomez, Shunichiro Kuramitsu, et al.
Archives of Dermatology|August 17, 2011
High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of responseBrian A Raphael, Daniel B Shin, Karen R Suchin, et al.
Blood|August 1, 2015
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphomaAlain H Rook, Joel M Gelfand, Joel C Gelfand, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|July 31, 2012
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsinYoun H Kim, Marie-France Demierre, Ellen J Kim, et al.
The Journal of Investigative Dermatology|August 24, 2007
IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndromeJessica S Yoon, Sarah M Newton, Maria Wysocka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2013
TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphomaEmmanuella Guenova, Rei Watanabe, Jessica E Teague, et al.
Journal of the American Academy of Dermatology|February 19, 2013
Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapyRachel S Klein, James D Dunlop, Sara S Samimi, et al.
Blood|January 13, 2006
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracyMichael Nebozhyn, Andrey Loboda, Laszlo Kari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaSean J Whittaker, Marie-France Demierre, Ellen J Kim, et al.
JAMA Dermatology|December 30, 2020
Brentuximab Vedotin for Relapsed or Refractory Sézary SyndromeDaniel J Lewis, Paul L Haun, Sara S Samimi, et al.
Blood Advances|April 14, 2023
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphomaKeisuke Watanabe, Angela M Gomez, Shunichiro Kuramitsu, et al.
Archives of Dermatology|August 17, 2011
High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of responseBrian A Raphael, Daniel B Shin, Karen R Suchin, et al.
Blood|August 1, 2015
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphomaAlain H Rook, Joel M Gelfand, Joel C Gelfand, et al.
Pageof 10